Your browser doesn't support javascript.
loading
Clinical outcome of patients with relapsed/refractory acute leukemia treated with FLAG-IDA regimen
Basquiera, Ana L; Prates, M Virginia; Moirano, María; García Erlich, Cecilia; Fazio, Patricia; Sturich, Ana G; Berreta, Adriana R; Gelemur, M; Millone, Jorge H; García, Juan J.
Afiliação
  • Basquiera, Ana L; Hospital Privado Centro Médico de Córdoba. Departamento de Hematología y Oncología. Córdoba. AR
  • Prates, M Virginia; ITMO Hospital Italiano. La Plata. AR
  • Moirano, María; s.af
  • García Erlich, Cecilia; s.af
  • Fazio, Patricia; s.af
  • Sturich, Ana G; Hospital Privado Centro Médico de Córdoba. Córdoba. AR
  • Berreta, Adriana R; Hospital Privado Centro Médico de Córdoba. Córdoba. AR
  • Gelemur, M; s.af
  • Millone, Jorge H; ITMO Hospital Italiano. La Plata. AR
  • García, Juan J; Hospital Privado Centro Médico de Córdoba. Córdoba. AR
Hematología (B. Aires) ; 13(2): 49-52, mayo-ago. 2009. tab, graf
Artigo em Inglês | LILACS | ID: lil-547257
Biblioteca responsável: AR67.1
ABSTRACT

Background:

Patients with Refractory/Relapsed (RIR) acute leukemia (AL) have a poor prognosis.

Objective:

We aimed to evaluate the chemotherapy regimen fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) in patients with RIR AL. Patients We studied 33 patients with R/R AL. Distribution of the AL subtype was myeloblastic n=17 (52%), lymphoblastic n=14 (42%),) and biphenotypic n=2 (6%).

Results:

Complete remission (CR) was achieved in 15 cases (45.5%) and seven patients dead resulting in a mortality of 21.1%. In patients with hematological recovery the median time to neutrophils recovery (> 0.5 x 10º/1) was 24 days (range 10-38); platelet levels of more than 20 x 1Oº/l and 50 x 10º/1 were reached in a median time of 24 (range 17-44) and 27 days (range 18-51), respectively. After CR, five patients underwent allogeneic transplan- tation and 10 patients received a second course of FLAG – IDA. Ten out of 15 patients who achieved CR with FLAG-IDA relapsed at a median of 7.7 months (95% CI 1.8 to 13.6 months). Overall survival (OS) after FLAG-IDA in the surviving cohort had a median of 4 months. We found a significantly better OS in patients who received allogeneic transplantation post-FLAG-IDA than those who did not (median 11.4 months vs. 2.7 monthsj HR 0.29; 95% CI 0.1 to 0.6; p=0.017).

Conclusions:

In our series, FLAG-IDA demonstrated to be an effective salvage chemotherapy regimen, however, the benefit in survival of this rescue treatment was restrained to patients who unde.rwent al1ogeneic transplantation
Assuntos
Buscar no Google
Coleções: Bases de dados internacionais Base de dados: LILACS Assunto principal: Transplante / Leucemia Tipo de estudo: Estudo prognóstico Idioma: Inglês Revista: Hematología (B. Aires) Assunto da revista: Hematologia Ano de publicação: 2009 Tipo de documento: Artigo País de afiliação: Argentina Instituição/País de afiliação: Hospital Privado Centro Médico de Córdoba/AR / ITMO Hospital Italiano/AR
Buscar no Google
Coleções: Bases de dados internacionais Base de dados: LILACS Assunto principal: Transplante / Leucemia Tipo de estudo: Estudo prognóstico Idioma: Inglês Revista: Hematología (B. Aires) Assunto da revista: Hematologia Ano de publicação: 2009 Tipo de documento: Artigo País de afiliação: Argentina Instituição/País de afiliação: Hospital Privado Centro Médico de Córdoba/AR / ITMO Hospital Italiano/AR
...